Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,454.00    38.00 (2.68%)
Bid:
1,454.00
Ask:
1,455.00
Spread: 1.00 (0.069%)
Market Cap: £3.09b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

10 Dec 2020 16:00

RNS Number : 2836I
Hikma Pharmaceuticals Plc
10 December 2020
 

Hikma Pharmaceuticals PLC

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Pledge by Darhold Limited of 1,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of J.P. Morgan (Suisse) SA. Darhold Limited is defined as a Person Closely Associated with the Executive Chairman, who is a director of and shareholder in Darhold Limited

c)

Price(s) and volume(s)

Price(s): £0.00p

Volume(s): 1,500,000

d)

Aggregated information

Aggregated volume: 1,500,000

Price: £0.00p

e)

Date of the transaction

10 December 2020

f)

Place of the transaction

Amman

 

 

 Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Pledge by Darhold Limited of 1,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of J.P. Morgan (Suisse) SA. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman, who is a director of and shareholder in Darhold Limited.

c)

Price(s) and volume(s)

Price(s): £0.00p

Volume(s): 1,500,000

d)

Aggregated information

Aggregated volume: 1,500,000

Price: £0.00p

e)

Date of the transaction

10 December 2020

f)

Place of the transaction

Amman

Mohammed 'Ali' Al-Husry

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mohammed 'Ali' Al-Husry

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Pledge by Darhold Limited of 1,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of J.P. Morgan (Suisse) SA. Darhold Limited is defined as a Person Closely Associated with the the Non-Executive Director, who is a director of and shareholder in Darhold Limited.

c)

Price(s) and volume(s)

Price(s): £0.00p

Volume(s): 1,500,000

d)

Aggregated information

Aggregated volume: 1,500,000

Price: £0.00p

e)

Date of the transaction

10 December 2020

f)

Place of the transaction

Amman

 

Peter SpeirsCompany Secretary, responsible for releasing this announcement+44 (0) 20 7399 2760

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBUBDDCUBDGGG
Date   Source Headline
12th Nov 20107:00 amRNSInterim Management Statement
9th Nov 20109:48 amRNSDirector/PDMR Shareholding
5th Nov 20103:37 pmRNSTotal Voting Rights
4th Nov 20104:15 pmRNSDirector/PDMR Shareholding
2nd Nov 201010:42 amRNSDirector/PDMR Shareholding
29th Oct 20107:00 amRNSAcquisition
18th Oct 20107:00 amRNSProduct Update
15th Oct 201011:10 amRNSBlock Listing for Share Schemes
4th Oct 20105:18 pmRNSTotal Voting Rights
4th Oct 20105:04 pmRNSBlocklisting Interim Review
1st Oct 20107:00 amRNSCompany Update
6th Sep 20103:53 pmRNSTotal Voting Rights
26th Aug 20107:00 amRNSInterim Results
4th Aug 20105:19 pmRNSVoting Rights and Capital
2nd Aug 201012:16 pmRNSAnnual Information Update
26th Jul 20105:30 pmRNSVoting Rights and Capital
13th May 20103:37 pmRNSAGM Statement
13th May 20107:00 amRNSInterim Management Statement
5th May 20105:48 pmRNSVoting Rights & Capital
23rd Apr 20103:16 pmRNSDirector/PDMR Shareholding
20th Apr 201010:02 amRNSDirector/PDMR Shareholding
12th Apr 20109:14 amRNSHikma expands in the Algerian market
9th Apr 20104:33 pmRNSAnnual Financial Report
9th Apr 201012:50 pmRNSDirector/PDMR Shareholding
9th Apr 201012:48 pmRNSDirector/PDMR Shareholding
8th Apr 201010:13 amRNSDirector/PDMR Shareholding
7th Apr 20107:00 amRNSHikma & CellTrion enter an exclusive partnership
7th Apr 20107:00 amRNSDirector/PDMR Shareholding
1st Apr 201012:23 pmRNSVoting Rights & Capital
1st Apr 201012:10 pmRNSBlocklisting Six Monthly return
30th Mar 20109:20 amRNSHikma expands in the Tunisian market
23rd Mar 20104:18 pmRNSDirector/PDMR Shareholding
17th Mar 20107:00 amRNSPreliminary Announcement for 2009
15th Mar 20109:43 amRNSBlocklisting of Shares
10th Mar 201011:00 amRNSTotal Voting Rights
1st Mar 20105:51 pmRNSNotice of Results
1st Feb 20101:40 pmRNSTotal Voting Rights
11th Jan 201012:00 pmRNSNon Regulatory Announcement
5th Jan 20102:10 pmRNSDirector/PDMR Shareholding
4th Jan 20106:28 pmRNSTotal Voting Rights
18th Dec 20093:17 pmRNSDirector/PDMR Shareholding
1st Dec 200910:05 amRNSTotal Voting Rights
1st Dec 200910:03 amRNSDirector/PDMR Shareholding
19th Nov 20093:07 pmRNSDirector/PDMR Shareholding
18th Nov 20094:37 pmRNSDirector/PDMR Shareholding
18th Nov 20094:29 pmRNSDirector/PDMR Shareholding
12th Nov 20097:00 amRNSInterim Management Statement
2nd Nov 200912:35 pmRNSTotal Voting Rights
20th Oct 200912:21 pmRNSBlocklisting Interim Review
16th Oct 200912:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.